Literature DB >> 15717273

Low seroprevalence of IgG antibodies to Ebola virus in an epidemic zone: Ogooué-Ivindo region, Northeastern Gabon, 1997.

Richard T Heffernan1, Bertin Pambo, Richard J Hatchett, Patricia A Leman, Robert Swanepoel, Robert W Ryder.   

Abstract

A population-based serosurvey was performed to determine the seroprevalence of antibodies to Ebola virus (EBO) in a region that has experienced multiple epidemics of EBO hemorrhagic fever. Of 2533 residents in 8 villages, serum samples from 979 (38.6%) were tested by enzyme-linked immunosorbent assay for immunoglobulin (Ig) G and IgM antibodies to Ebola-Zaire (EBO-Z) virus. Fourteen samples (1.4%) were found positive for IgG antibodies, and 4 of these (.4%) were samples from survivors of an epidemic of EBO hemorrhagic fever. Seroprevalence based on the remaining 10 IgG-seropositive individuals with no history of exposure to EBO was 1.0% (exact binomial 95% confidence interval, 0.5%-1.9%). No serum samples were found positive for IgM antibodies to EBO-Z virus. The low seroprevalence suggests that, outside of recognized outbreaks, human exposure to EBO in this epidemic zone is rare.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717273     DOI: 10.1086/427994

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Ebola control: effect of asymptomatic infection and acquired immunity.

Authors:  Steve E Bellan; Juliet R C Pulliam; Jonathan Dushoff; Lauren Ancel Meyers
Journal:  Lancet       Date:  2014-10-15       Impact factor: 79.321

2.  What Ebola tells us about outbreak diagnostic readiness.

Authors:  Mark D Perkins; Mark Kessel
Journal:  Nat Biotechnol       Date:  2015-05       Impact factor: 54.908

3.  Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus.

Authors:  Verena Krähling; Dirk Becker; Cornelius Rohde; Markus Eickmann; Yonca Eroğlu; Astrid Herwig; Romy Kerber; Katharina Kowalski; Júlia Vergara-Alert; Stephan Becker
Journal:  Med Microbiol Immunol       Date:  2015-10-16       Impact factor: 3.402

4.  Serologic Evidence of Ebolavirus Infection in a Population With No History of Outbreaks in the Democratic Republic of the Congo.

Authors:  Sabue Mulangu; Vivian H Alfonso; Nicole A Hoff; Reena H Doshi; Prime Mulembakani; Neville K Kisalu; Emile Okitolonda-Wemakoy; Benoit Ilunga Kebela; Hadar Marcus; Joseph Shiloach; Je-Nie Phue; Linda L Wright; Jean-Jacques Muyembe-Tamfum; Nancy J Sullivan; Anne W Rimoin
Journal:  J Infect Dis       Date:  2018-01-30       Impact factor: 5.226

5.  Anatomy of a Hotspot: Chain and Seroepidemiology of Ebola Virus Transmission, Sukudu, Sierra Leone, 2015-16.

Authors:  J Daniel Kelly; Mohamed Bailor Barrie; Annelies W Mesman; Sahr Karku; Komba Quiwa; Michael Drasher; Gabriel Warren Schlough; Kerry Dierberg; Songor Koedoyoma; Christina P Lindan; James Holland Jones; Gabriel Chamie; Lee Worden; Bryan Greenhouse; Sheri D Weiser; Travis C Porco; George W Rutherford; Eugene T Richardson
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

6.  Evaluating the frequency of asymptomatic Ebola virus infection.

Authors:  Placide Mbala; Marc Baguelin; Ipos Ngay; Alicia Rosello; Prime Mulembakani; Nikolaos Demiris; W John Edmunds; Jean-Jacques Muyembe
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2017-05-26       Impact factor: 6.237

7.  High prevalence of both humoral and cellular immunity to Zaire ebolavirus among rural populations in Gabon.

Authors:  Pierre Becquart; Nadia Wauquier; Tanel Mahlakõiv; Dieudonné Nkoghe; Cindy Padilla; Marc Souris; Benjamin Ollomo; Jean-Paul Gonzalez; Xavier De Lamballerie; Mirdad Kazanji; Eric M Leroy
Journal:  PLoS One       Date:  2010-02-09       Impact factor: 3.240

Review 8.  Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection.

Authors:  Natalie E Dean; M Elizabeth Halloran; Yang Yang; Ira M Longini
Journal:  Clin Infect Dis       Date:  2016-02-29       Impact factor: 9.079

9.  A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa.

Authors:  Angela Huttner; Christophe Combescure; Stéphane Grillet; Mariëlle C Haks; Edwin Quinten; Christine Modoux; Selidji Todagbe Agnandji; Jessica Brosnahan; Julie-Anne Dayer; Ali M Harandi; Laurent Kaiser; Donata Medaglini; Tom Monath; Pascale Roux-Lombard; Peter G Kremsner; Tom H M Ottenhoff; Claire-Anne Siegrist
Journal:  Sci Transl Med       Date:  2017-04-12       Impact factor: 17.956

10.  Immunoglobulin G in Ebola outbreak survivors, Gabon.

Authors:  Nadia Wauquier; Pierre Becquart; Clélia Gasquet; Eric M Leroy
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.